Article
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Expert review of molecular diagnostics - 1 Dec 2016
Hsiue Emily Han-Chung, Lee Jih-Hsiang, Lin Chia-Chi, Yang James Chih-Hsin
Abstract excerpt
INTRODUCTION: Gefitinib is recently approved by the US Food and Drug Administration as a first-line treatment for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. The therascreen® EGFR RGQ PCR Kit is approved as a companion diagnostic to select patients with EGFR exon 19 deletions and L858R mutation for treatment with gefitinib. Areas covered: This article reviews the methods for detecting...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.